Insulin-like stimulation of cardiac fuel metabolism by physiological levels of glucagon: involvement of PI3K but not cAMP

Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island Submitted 11 February 2008 ; accepted in final form 14 May 2008 At concentrations around 10 –9 M or higher, glucagon increases cardiac contractility by activating adenylate c...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology: endocrinology and metabolism Vol. 295; no. 1; pp. E155 - E161
Main Authors Harney, Julie A, Rodgers, Robert L
Format Journal Article
LanguageEnglish
Published United States American Physiological Society 01.07.2008
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island Submitted 11 February 2008 ; accepted in final form 14 May 2008 At concentrations around 10 –9 M or higher, glucagon increases cardiac contractility by activating adenylate cyclase/cyclic adenosine monophosphate (AC/cAMP). However, blood levels in vivo, in rats or humans, rarely exceed 10 –10 M. We investigated whether physiological concentrations of glucagon, not sufficient to increase contractility or ventricular cAMP levels, can influence fuel metabolism in perfused working rat hearts. Two distinct glucagon dose-response curves emerged. One was an expected increase in left ventricular pressure (LVP) occurring between 10 –9.5 and 10 –8 M. The elevations in both LVP and ventricular cAMP levels produced by the maximal concentration (10 –8 M) were blocked by the AC inhibitor NKY80 (20 µM). The other curve, generated at much lower glucagon concentrations and overlapping normal blood levels (10 –11 to 10 –10 M), consisted of a dose-dependent and marked stimulation of glycolysis with no change in LVP. In addition to stimulating glycolysis, glucagon (10 –10 M) also increased glucose oxidation and suppressed palmitate oxidation, mimicking known effects of insulin, without altering ventricular cAMP levels. Elevations in glycolytic flux produced by either glucagon (10 –10 M) or insulin (4 x 10 –10 M) were abolished by the phosphoinositide 3-kinase (PI3K) inhibitor LY-294002 (10 µM) but not significantly affected by NKY80. Glucagon also, like insulin, enhanced the phosphorylation of Akt/PKB, a downstream target of PI3K, and these effects were also abolished by LY-294002. The results are consistent with the hypothesis that physiological levels of glucagon produce insulin-like increases in cardiac glucose utilization in vivo through activation of PI3K and not AC/cAMP. insulin; glycolysis; phosphoinositide 3-kinase; cyclic adenosine monophosphate Address for reprint requests and other correspondence: R. L. Rodgers, Dept. of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Univ. of Rhode Island, 345 Fogarty Hall, Kingston, RI 02881 (e-mail: rrodgers{at}uri.edu )
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Address for reprint requests and other correspondence: R. L. Rodgers, Dept. of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Univ. of Rhode Island, 345 Fogarty Hall, Kingston, RI 02881 (e-mail: rrodgers@uri.edu)
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
ISSN:0193-1849
1522-1555
DOI:10.1152/ajpendo.90228.2008